[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100551404":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":30,"centralContacts":34,"locations":42,"responsibleParty":164,"collaborators":10,"id":167,"slug":168,"hasResults":169,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":169,"sex":175,"minAge":176,"maxAge":177,"enrollmentInfo":178,"targetDuration":181,"studyType":182,"phases":10,"briefSummary":183,"conditions":184,"keywords":186,"overallStatus":45,"whyStopped":10,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":212},{"fullName":5,"class":6},"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with migraine under treatment with monoclonal antibodies against CGRP",null,"Patients with diagnosis of episodic or chronic migraine who, under the criteria of their neurologist and according to the clinical practice guidelines and standard of care, receive treatment with monoclonal antibodies against CGRP (Galcanezumab, Fremanezumab, Eptinezumab) or else its receptor (Erenumab) will be included.",[13,14,15],"Other: Headache record","Other: Scales","Drug: Monoclonal antibody anti-CGRP",[17,21,25],{"type":6,"name":18,"description":19,"armGroupLabels":20,"otherNames":10},"Headache record","The patient will keep a record of the presence\u002Fabsence of headache, average intensity, and need for acute medication.",[9],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"Scales","Each patient performs different scales that measure the impact of the migraine on their daily life as well as the disability it may be causing. In turn, each patient performs different scales that measure associated comorbidities such as depression, anxiety or insomnia.",[9],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":10},"DRUG","Monoclonal antibody anti-CGRP","Erenumab, Galcenazumeb, Fremanezumab, Eptinezumab",[9],[31],{"name":32,"affiliation":5,"role":33},"Ana Beatriz Gago Veiga","PRINCIPAL_INVESTIGATOR",[35,39],{"name":32,"role":36,"phone":37,"phoneExt":10,"email":38},"CONTACT","+34 915202416","anabeatriz.gago@salud.madrid.org",{"name":40,"role":36,"phone":10,"phoneExt":10,"email":41},"Iris Fernández Lázaro","irisfdezlaz@gmail.com",[43,64,79,97,115,134,150],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Hospital Clínico Universitario Lozano Blesa","RECRUITING","Zaragoza","Aragon","50009","Spain","ES",{"type":52,"coordinates":53},"Point",[54,55],-0.87734,41.65606,{"lat":55,"lon":54},[58,63],{"name":59,"role":36,"phone":60,"phoneExt":61,"email":62},"Sonia Santos-Lasaosa","+34 976765700","162354","ssantos@salud.aragon.es",{"name":59,"role":33,"phone":10,"phoneExt":10,"email":10},{"facility":65,"status":45,"city":66,"state":67,"zip":68,"country":49,"countryCode":50,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"Hospital Universitario Donostia","Donostia \u002F San Sebastian","Basque Country","20014",{"type":52,"coordinates":70},[71,72],-1.97499,43.31283,{"lat":72,"lon":71},[75,78],{"name":76,"role":36,"phone":10,"phoneExt":10,"email":77},"Ane Mínguez Olaondo","ane.minguezolaondo@osakidetza.eus",{"name":76,"role":33,"phone":10,"phoneExt":10,"email":10},{"facility":80,"status":45,"city":81,"state":82,"zip":83,"country":49,"countryCode":50,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"Hospital Universitario Marqués de Valdecilla","Santander","Cantabria","39008",{"type":52,"coordinates":85},[86,87],-3.80493,43.46589,{"lat":87,"lon":86},[90,94,96],{"name":91,"role":36,"phone":92,"phoneExt":10,"email":93},"Julio Pascual Gómez","+34 942202520","julio.pascual@scsalud.es",{"name":95,"role":36,"phone":10,"phoneExt":10,"email":10},"Gabriel Gárate",{"name":91,"role":33,"phone":10,"phoneExt":10,"email":10},{"facility":98,"status":45,"city":99,"state":100,"zip":101,"country":49,"countryCode":50,"cosmosGeoPoint":102,"geoPoint":106,"contacts":107},"Hospital Clínico Universitario de Valladolid","Valladolid","Castille and León","47010",{"type":52,"coordinates":103},[104,105],-4.72353,41.65541,{"lat":105,"lon":104},[108,112,114],{"name":109,"role":36,"phone":110,"phoneExt":10,"email":111},"David García Azorín","+34 983420000","davilink@hotmail.com",{"name":113,"role":36,"phone":10,"phoneExt":10,"email":10},"Yésica González Osorio",{"name":109,"role":33,"phone":10,"phoneExt":10,"email":10},{"facility":116,"status":45,"city":117,"state":118,"zip":119,"country":49,"countryCode":50,"cosmosGeoPoint":120,"geoPoint":124,"contacts":125},"Hospital Universitari Vall d'Hebron Research Institute","Barcelona","Catalonia","08035",{"type":52,"coordinates":121},[122,123],2.15899,41.38879,{"lat":123,"lon":122},[126,131,133],{"name":127,"role":36,"phone":128,"phoneExt":129,"email":130},"Patricia Pozo-Rosich","+34 934893000","2479","patricia.pozo@vallhebron.cat",{"name":132,"role":36,"phone":10,"phoneExt":10,"email":10},"Edoardo Caronna",{"name":127,"role":33,"phone":10,"phoneExt":10,"email":10},{"facility":135,"status":45,"city":136,"state":136,"zip":137,"country":49,"countryCode":50,"cosmosGeoPoint":138,"geoPoint":142,"contacts":143},"Hospital Universitario de La Princesa","Madrid","28006",{"type":52,"coordinates":139},[140,141],-3.70256,40.4165,{"lat":141,"lon":140},[144,145,146,147],{"name":32,"role":36,"phone":37,"phoneExt":10,"email":38},{"name":40,"role":36,"phone":10,"phoneExt":10,"email":41},{"name":32,"role":33,"phone":10,"phoneExt":10,"email":10},{"name":148,"role":149,"phone":10,"phoneExt":10,"email":10},"Alicia González Martínez","SUB_INVESTIGATOR",{"facility":151,"status":45,"city":152,"state":152,"zip":153,"country":49,"countryCode":50,"cosmosGeoPoint":154,"geoPoint":158,"contacts":159},"Hospital Universitario Politécnico La Fe","Valencia","46026",{"type":52,"coordinates":155},[156,157],-0.37966,39.47391,{"lat":157,"lon":156},[160,163],{"name":161,"role":36,"phone":10,"phoneExt":10,"email":162},"Samuel Díaz Insa","diaz_sam@gva.es",{"name":161,"role":33,"phone":10,"phoneExt":10,"email":10},{"type":33,"investigatorFullName":165,"investigatorTitle":166,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Ana Gago","Head of the Headache Unit","100551404","study-for-prevent-chronification-migraine-through-prediction-of-response-to-treatment-with-anti-cgrp-antibodies-100551404",false,"NCT06459648","Study for Prevent Chronification Migraine Through Prediction of Response to Treatment With Anti-CGRP Antibodies","Prediction Study or Response to Treatment With Anti-CGRP Monoclonal Antibodies in Migraine","PREDI-CGRP","Inclusion Criteria:\n\n* Patients aged between 18 and 65 years.\n* Caucasian ethnicity.\n* Patients diagnosed with migraine with and without high-frequency episodic aura (more than 8 days of migraine per month) or chronic by a neurologist expert in headaches and according to the criteria proposed in the International Classification of Headache Diseases, 3rd edition (ICHD- 3).\n* Have at least one year of history of migraine.\n* Patients must maintain stable preventive treatment in the previous month and not have received botulinum toxin in the month prior to starting the monoclonal antibody.\n* Patients able to describe their clinical situation and the characteristics of their headache.\n* Grant your informed consent.\n\nExclusion Criteria:\n\n* Patients who present with another type of non-migraine headache, with the exception of headache due to excessive use of analgesic medication.\n* Neurological focus in the examination.\n* Pregnancy or breastfeeding period.\n* Patients with cognitive deficiency or pathology that may prevent or hinder the correct completion of the study.\n* Patients who require changes in preventive treatment during the first 6 months after starting treatment with monoclonal antibodies.\n* Patients who present any significant adverse effect that requires withdrawal or change of anti-CGRP drug.","ALL","18 Years","65 Years",{"count":179,"type":180},350,"ESTIMATED","18 Months","OBSERVATIONAL","Being able to predict each patients response to a specific treatment can mean a significant improvement in socioeconomic costs, but above all in their quality of life. With the present study, the investigators aim to analyze in a combined way different clinical, biological and neuroimaging variables, which allow the clinical staff to anticipate the response to treatment with anti-CGRP monoclonal antibodies in patients with migraine.",[185],"Migraine",[185,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202],"headache","antibodies","antibody","monoclonal antibody","anti-cgrp","anti cgrp","cgrp","prediction","treatmen","migraine treatment","treatment with anti-CGRP monoclonal antibodies","anti-cgrp antibodies","anti-cgrp antibody","anti-cgrp monoclonal antibodies","migraine and antibodies","migraine and cgrp","2026-06-30",{"date":205,"type":206},"2026-07-02","ACTUAL",{"date":208,"type":206},"2023-04-26",{"date":210,"type":180},"2026-07",{"name":5,"class":6},7]